The War on Cancer: Two Sides to Every Story

NOTE: The following was originally offered as a two-part presentation by the author dealing with both the “losing” and what he believed to be the “winning” side of the issue. We present both sides of the war in a single posting for your education and consideration. ~ Ed.

Part I: Losing the War on Cancer

In 1971, President Richard Nixon announced the War on Cancer and promised a cure by the 1977 bicentennial. In 2009 death rates from cancer are significantly increased and…..no cure is forthcoming! The failure of chemotherapy to control cancer has become apparent even to the oncology establishment. Scientific American featured a recent cover story entitled: “The War on Cancer — it’s Being Lost.” In it, eminent epidemiologist John C. Bailar III, MD, PhD, Chairman of the Department of Epidemiology and Biostatistics at McGill University cited the relentless increase in cancer deaths in the face of growing use of toxic chemotherapy. He concluded that scientists must look in new directions if they are ever to make progress against this unremitting killer.

Cancer incidences have grown from 1 in 500 to nearly 1 in 2 today!

Cancer remains the second leading killer in most Western industrialised nations and has crept from an incidence rate of around 1 in 500 in 1900 to 1 in 2 to 3 today. In the last 30 years there has been an 80% increase in breast cancer, a 100% increase in prostate cancer, an overall increase of 49% cancer incidence in men and 41% in women. Embodied in these facts are 2 key realities. Firstly, we are not treating cancer effectively (see below) and second, we are not preventing it!

Recently, 3 Oncologists published a key meta-analysis “The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies” in the journal Clinical Oncology (Morgan et al, 2004). Their study was based on an analysis of the results of all the randomized, controlled clinical trials (RCTs) performed in Australia and the US that reported a statistically significant increase in 5-year survival due to the use of chemotherapy in adult malignancies. Survival data were drawn from the Australian cancer registries and the US National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) registry spanning the period January 1990 until January 2004. Wherever data were uncertain, the authors deliberately erred on the side of over-estimating the benefit of chemotherapy. Even so, the study concluded that overall, chemotherapy contributes just over 2 percent to improved survival in cancer patients! The authors found that the contribution of chemotherapy to 5-year survival in adults was 2.3 percent in Australia, and 2.1 percent in the USA. They emphasize that, for reasons explained in detail in the study, these figures “should be regarded as the upper limit of effectiveness” (i.e., they are an optimistic rather than a pessimistic estimate).

Why would such a key study be greeted with complete silence on this side of the world? Some practitioners still remain optimistic that cytotoxic chemotherapy will significantly improve cancer survival,” the authors wrote in their introduction. “However, despite the use of new and expensive single and combination drugs to improve response rates…there has been little impact from the use of newer regimens” (Morgan et al 2004).

At very best the worldwide success rate of chemotherapy is not more than 3%

These published statistics should not be surprising since 12 years earlier in 1992 a German epidemiologist, Dr. Ulrich Abel published a review and analysis on clinical trials of chemotherapy. He sent letters to over 350 medical centres around the world asking them to send him anything they had published on the subject. The analysis took him several years, but the results? The overall worldwide success rate of chemotherapy was only 3%. There was simply no scientific evidence available anywhere that chemotherapy can “extend in any appreciable way the lives of patients suffering from the most common organic cancers.”

To some cancer sufferers the above figures may not tally with the figures that may have been presented to prior to them prior to their chemotherapy option. The following might explain the disparity.

Oncologists frequently express the benefits of chemotherapy in terms of “relative risk” rather than giving a direct assessment of the likely impact on overall survival. Relative risk is a statistical means of expressing the benefit of receiving a medical intervention in a way that, while technically accurate, has the effect of making the intervention look considerably more beneficial than it truly is.

For example if a treatment causes a patient’s risk to drop from 4 percent to 2 percent, this can be expressed as a decrease in relative risk of 50 percent. On face value that sounds good. But another, equally valid way of expressing this is to say that it offers a 2 percent reduction in absolute risk, which is less likely to convince patients to take the treatment.

When results were expressed as a relative risk reduction, physicians believed the drugs were more effective and were strongly more inclined to prescribe than they were when the identical results were expressed as an absolute risk reduction (Bucher 1994). This is not necessarily an attempt on the Physicians part to be misleading but doctors need to be wary of the way that results are presented to them by those that have a vested interest!

The way that medical information is reported in the professional literature therefore clearly has an important influence on the treatment recommendations oncologists make. A drug that can be said, for example, to reduce cancer recurrence by 50 percent, is likely to get the attention and respect of oncologists and patients alike, even though the absolute risk may only be a small one – perhaps only 2 or 3 percent – and the reduction in absolute risk commensurately small.

Further confusion and contribution to elevated claims are the use of other surrogate end points such as ‘progression-free survival,’ ‘disease-free survival’ or ‘recurrence-free survival’ and these may only reflect temporary lulls in the progression of the disease. Such temporary stabilization of disease, if it occurs at all, seldom lasts for more than a few months at best. A correlation between shrinking a tumour and extending the life of the patient does not necessarily exist.

So, if you want to know how good a proposed chemotherapy is for you…….ask your Oncologist to tell you what is the reduction in ABSOLUTE RISK that you will achieve by having the therapy. Either, he/she will not know the answer or the true picture is likely to be not so optimistic.

The cancer industry has a turnover in excess of $200 billion annually

The reality could not be stated more clearly than by Albert Braverman, M.D., in the Lancet in 1991 “Many oncologists recommend chemotherapy for almost any type of cancer, with a faith that is unshaken by the almost constant failures”.

Putting aside for a moment the failure of science to support the widespread first line use of chemotherapy there is also the detrimental effects on quality of life that must be considered. Taken together…..we must surely, by now, have found a better way? Is a change of track not long overdue? The cancer industry turns over in excess of $200 billion annually. It is hard to believe that economics would be in the “driving seat” of this business or that this industry even remains a viable business when the outcomes are so poor. It is fear that drives most patients to accept chemotherapy together with a perhaps an unrealistic expectation of its success based on the ways that this information is conveyed to them. If we combine these ingredients with the lack of a medically-endorsed alternative treatment then we have a recipe for “Today’s cancer Therapy.”

The WHO states that at least one third of all cancer cases are preventable

As I see it there are several things that need to happen before the current tide of failure against cancer can be turned. (The following are listed in no particular order):

* Cancer therapeutics should be driven by health benefit and not by economics

* Chemotherapy should now be accepted as a failed tool in the battle and we should look away from toxic chemicals for a more effective solution. Perhaps the law around patenting of natural compound formulations needs to be re-considered.

* There are several evidence-based non-toxic therapies for cancer that have a better success in remitting cancers (some achieving 70% or more 5 year remission). I will go into more details of this in Part 2 of this article ‘Winning the War on Cancer.’

* Doctors should be trained in Nutritional Medicine and Preventative Medicine especially as scientific evidence accumulates in support of the gene-regulating and therefore cell-regulating role of key nutrients.

* We need to detect cancer earlier. For example by the time a tumour can be seen on a mammogram it is the size of a small grape, representing 500 million cancer cells. The adjunctive use of thermal imaging would allow detection 6 to 10 years sooner.

* A firm acknowledgement within the Medical fraternity that cancer is preventable. The WHO states that at least one-third of all cancer cases are preventable. Clearly they are right and if we added in the statistic of 50% reduction in risk of most cancers by correct dietary changes then we are dealing with very significant reductions in absolute risk of most cancers. Even breast cancer is only familial in approximately 8% of cases, suggesting that 92% are environmentally-caused, and by this we mean internal as well as external environment.

* Acknowledgement of and clear identification of chemicals, toxins or drugs in the external environment that increase risk with serious consideration to implementing ways to reduce them and/or exposure to them.

In the last section of this article I would like to focus briefly on the role of nutrition in cancer prevention. There are more lessons to be learned here then we may think and particularly if we still have the mindset that nutrition is just fuel for energy, growth and repair. Consider the following 2 summary statements:

* A review of 172 case-controlled prospective studies, comparing low verses high quartile of food consumption, showed that low fruit and vegetable consumption resulted in double the risk of cancer for most sites. (Block et al, Nutr Cancer Inst, 1992, 18: 1-29)

* 150 scientists reviewed 4,500 research studies on the relationship between nutrition and cancer. They found overwhelming evidence that fruits, vegetables, and grains can prevent cancer. (Cancer Prevention Research Program, 1997)

This is so important! It means that the 90% of Western populations that do not eat 5 or more portions of fruit and vegetables per day are increasing their risk of getting cancer. The risk is further compounded by addition of excess animal protein intake to this phytonutrient deficit. There is published association of animal protein intake and cancer incidence (Campbell & Campbell, 2006). This information on fruit and vegetables has led to a plethora of research on the value of anti-oxidants in cancer prevention.

What has emerged from these prospective studies is the paradoxical finding that large doses of individual anti-oxidants like Vitamin E, and beta carotene do not make any difference to cancer incidence. (Greenberg et al, 1994; Alpha-tocopherol, Beta carotene, Cancer Prevention study group, 1994; Hankinson et al, 1994; Omenn et al, 1996; Hennekens et al, 1996).

So whilst a synergy of plant-based nutrients seems to have a preventative effect, isolated anti-oxidant nutrients do not. If we look at the published scientific literature on phytonutrients we discover several important clues as to how to prevent and treat cancer. Firstly, fruit and vegetables consist of thousands of different families of nutrients e.g. Carotenoids, Flavenoids (Flavenols, Flavones, Flavenones, Isoflavones, Catechins, Anthocyanidins, Chalcones), Isoflavones (Phytoestrogens), Isothiocyanates, Organosulphur compounds, Monoterenes/Terpenoids, Resveratrols.

As well as providing ample anti-oxidant activity these compounds have several other important published biological actions. They decrease DNA damage, improve cell communication, improve cell detoxification, are anti-inflammatory, boost Immunity, improve circulation and alter gene expression. In fact, they seem to be critically involved in the regulation of cell growth, cell cycle, apoptosis and signal transduction.
Nature is giving us the clue that cancer control requires the combination of multiple substances working in synergy.

Above is a chart from the Journal of Nutrition and Cancer (2001). It shows 9 different ways that cruciferous vegetables can be anti-cancer. Six of these mechanisms involve a nutrient-gene interaction….Nutrigenomics. This has become a rapidly expanding science. It seems that phytonutrients play a key role in human gene regulation.

As cancer is essentially a cell dysregulation and plant nutrients have multiple cell regulatory actions, it becomes apparent that diets rich in these nutrients can offer protection against cancer. It is almost certain that this protective effect is NOT just based on an anti-oxidant action. Trying to fix cancer with single specific targeted compounds is not likely to be ever fruitful and yet this blinkered approach occupies almost exclusively the attention of the chemical-based Pharmaceutical Industry.

Nature is giving us the clue that cancer control requires the combination of multiple substances working in synergy but affecting cell regulation by different mechanisms. Targeting the controlling centers of cell regulation within the cell is likely to be a fruitful focus for cancer control.

~ References ~

1. Abel, U., ‘Chemotherapy of Advanced Epithelial Cancer: a critical review’, Biomedicine and Pharmacotherapy, 1992; 46: 439-452.

2. Alpha-tocopherol, Beta carotene, Cancer Prevention study group. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers, N Engl J Med. 1994; 330: 1029-1035

3. Braverman,A, “Medical Oncology in the 90s”, Lancet, 1991, Vol. 337, p. 901

4. Bucher HC, Weinbacher M, Gyr K. Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. BMJ. 1994;309:761-764.

5. Campbell, TC, Campbell, TM. The China Study, 2006, BenBella books

6. Greenberg, ER; Baron, JA; Tosteson, TD. A clinical trial of antioxidant vitamins to prevent colorectal adenoma, N Engl J Med. 1994;331: 141-147

7. Hankinson, SE, Stampfer, MJ. All that glitters is not beta carotene. JAMA, 1994; 272:1455-1456

8. Hennekens CH, Buring JE, Manson JE. Lack of effect of long term supplementation with beta carotene on the incidence of malignant neoplasm and cardiovascular disease, N Engl J med. 1996; 334: 1145-1149

9. Morgan G, Ward R, Barton M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies, Clin Oncol (R Coll Radiol), 2004;16(8):549-60.

10. Murillo, G; Mehta, RG: Cruciferous Vegetables and Cancer Prevention, Nutrition and Cancer, Volume 41, Issue 1 & 2 September 2001,17 – 28

11. Omenn GS, Goodman GE, Thornquist MD. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease, N Engl J Med. 1996; 334: 1150-1155

Part II: Winning the War on Cancer

In the previous article ‘Losing the War on Cancer’ I discussed the current failure of chemotherapy to turn the tide of increasing incidence of cancer. I looked at the reasons why this was the case. I discussed the clues from Nature that suggest that the cancer prevention actions of the phyto-nutrients in fruit and vegetables are likely to be due to a range of nutrient-gene interactions and not just an anti-oxidant effect.

Specific phyto-nutrients decrease DNA damage, improve cell communication, improve cell detoxification, are anti-inflammatory, boost Immunity and improve circulation and there may be other as yet undefined actions of phyto-nutrients that are relevant to their cancerostatic effect.

The key to unravelling the cancer mystery I believe lies in correctly identifying the mechanisms by which a normal regulated cell becomes an ‘unruly’ /unregulated one.

The cell is exceedingly complicated and subtle machinery in which all functions are carefully regulated. For example, a normal cell divides only when division is needed, but a cancer cell divides also when no division is needed. This means that the cell regulators are out of order. Many efforts to show the difference between the chemical makeup of a normal and a cancer cell have hitherto failed. The cellular structures are identical, only the regulators are disturbed. Something has gone wrong that has to be repaired.

How does a normal cell become unregulated?
In recent years there has been a great deal of focus on the possible assaults on a cell that may cause it to mutate and become abnormal. Does a virus or a toxin or free radical cause damage to DNA and lead to an alteration in the cells regulatory genes, for example, those involved in normal programmed cell death? Interesting though this is in theory and it has not led to any major solution to the cancer problem.

There have been some historical clues to suggest that a fundamental flaw that occurs in all cancers is a disturbance in cell metabolism, that makes the cell prefer a fermentation of glucose (using glycolysis) for energy production rather than the more efficient oxidative metabolism (which requires oxygen and generates much more energy).

(Warburg, 1930; Szent-Gyorgyi et al, 1963). It seems that this switch to fermentation may be a mechanism for allowing cell division and therefore growth to occur and may be the process that normally happens when the cell needs to divide. After this normal cell division the process then reverts back to oxidative metabolism, with its associated electron flow, and which requires a more organised cell structure. Therefore, it may be that the uncontrolled growth of cancer cells is associated with them being stuck in a fermentation process. We must then ask the question – What keeps them stuck in this process? Or what turns off the ability of the cell to revert back to a normal oxidative cell metabolism – which seems to be associated with cell regulation?

These arguments are not new and have been presented before by Albert Szent-Gyorgyi, the Hungarian-born Nobel Prize winner, in the 1950s and 60s. (Dr. Albert Szent-Gyorgyi was the Nobel Laureate in Medicine in 1937 for the isolation and discovery of Vitamin C. Known as the ‘Father of Nutritional Science,’ he also discovered isoflavones and vitamin P. In his last 40 years, he researched the regulatory processes of cell growth, and thereby the regulation of cancer itself).

Otto Warburg

Otto Warburg in 1930 championed the fact that anoxia is the cause of cancer. The first notable experimental induction of cancer by oxygen deficiency was described by Goldblatt and Cameron (1953), who exposed heart fibro¬blasts in tissue culture to intermittent oxygen deficiency for long periods and finally obtained transplantable cancer cells, whereas in control cultures that were maintained without oxygen deficiency, no cancer cells resulted. Warburg emphasized; “But there is only one common cause into which all other causes of cancer merge, the irreversible injuring of respiration.” I will present evidence later that this change in cell respiration may not be irreversible after all.

One of the many mysteries about muscles is the fact that they rarely develop cancer. This may be because they are so dependent on oxygen and oxidative metabolism or so rich in mitochondria, the power centres of the cell, that there is too much oxidative reserve for cancer to develop.

It is now well accepted that most cancers are more glycolysis-dependent than normal cells. Cancer cells have lost their capacity to conduct oxidations, and also the mechanisms that use the energy of oxidation for useful work. Instead a low-grade process, wasteful fermentation, is used to produce energy. As stated above, this may be the norm for the cell when it wants to divide. Positron emission tomography (PET) imaging has now confirmed that most malignant tumours have increased glucose uptake and metabolism. Warburg suggested, but did not prove, that this was due to ‘‘abnormal mitochondria’’ (Warburg, 1930); that is, cancer cells are forced to use inefficient, non-mitochondrial means of generating ATP (the energy unit of cells). Szent-Gyorgyi was also of the opinion that this apparent mitochondrial ‘‘dysfunction’’ is in fact reversible. It was his research that suggested that this fermentation energy is transferred to the mitotic mechanism, where it forces cell division. In other words as stated earlier, efficient oxidative energy production is associated with organised cell structure, whereas fermentation is associated with lack of structure and the inclination to cell division. When cancer cells multiply they are merely performing an innate function.

It has been reported that human cancer cell lines have a more negative membrane potential compared to several non-cancerous cell lines, suggesting that this might be a hallmark of malignancy (Bonnet et al, 2007). Since a significant proportion of cell energy production (70% or more) is channelled towards maintaining electrical integrity by supporting the ion pumps at the cell membrane, it becomes clear that this abnormal membrane potential of cancer cells is likely to be secondary to the cell being “metabolically” compromised.

Mitochondrial function and cancer
Mitochondria are the seat of energy production in the cell producing 80% of the energy needs of the cell. Several differences have been observed between the mitochondria of cancer cells and those of normal cells. It has been suggested that mutations in mitochondria might cause cancer (Woods & DuBuy, 1945). More recently it has been shown that mitochondria are integrally involved in apoptosis or programmed cell death, (Petit & Kroemer,1998; Zamzami et al, 1996).

The mitochondria contain their own DNA (less then 1% of nuclear DNA), which seems to be more susceptible to damage and mutations than nuclear DNA. The accumulation of mutations in mitochondrial DNA has also been suggested to play a causative role in ageing. Various tumour cell lines exhibit differences in the number size and shape of mitochondria relative to normal controls. The mitochondria of rapidly-growing tumours tend to be fewer in number, smaller and have fewer internal folds than mitochondria of slowly growing tumours. Alterations in the inner membrane composition of tumour mitochondria have also been noted (Modica-Napolitano & Singh, 2002). The mitochondrial membrane potential of cancer cells is approximately 60mV higher than that of control epithelial cells (Modica-Napolitano & Aprille, 1987). Mitochondrial dysfunction is one of the most profound features of cancer cells.

Cancer progression and its resistance to treatment depend, at least in part, on suppression of apoptosis (programmed cell death). As stated above, mitochondria are recognized as regulators of apoptosis.

We have already established that cancer seems to be associated with a glycolytic phenotype. Furthermore, it appears that glycolytic phenotype is indeed associated with a state of apoptosis resistance (Plas and Thompson, 2002). Many glycolytic enzymes have been recognized to also regulate apoptosis, and several onco-proteins induce the expression of glycolytic enzymes (Kim and Dang, 2005).

All the available evidence suggests that if we want to understand cancer better and find a remedy then we have to turn our attention specifically to mitochondria, for it is here that the energy malfunctions that occur in cancer are to be found.

Mitochondrial changes have multiple downstream effects, beyond energy production, because mitochondria regulate several critical functions including calcium concentration and free radical (Reactive Oxygen Species, ROS)-redox control. Mitochondria have an important role in apoptosis that may explain the apoptosis resistance that occurs in many human cancers.

Cancer cells have been shown to have more hyperpolarized mitochondria and were relatively deficient in potassium channels. If this metabolic-electrical remodelling is an adaptive response, then its reversal might increase apoptosis and inhibit cancer growth. The Michelakis research group showed that dichloroacetate (DCA), a small, orally available small molecule and a well-characterized inhibitor of the key enzyme in the glycolytic chain, pyruvate dehydrogenase, was able to change the metabolism of cancer cells from the cytoplasm-based glycolysis to the mitochondria-based glucose oxidation.

DCA also reversed the inhibition of potassium channels in all cancer, but not normal cells. The net effect was a reversal of resistance to apoptosis (Bonnet et al, 2007). DCA treatment significantly increases glucose oxidation (which only occurs in functional mitochondria), indicating that the metabolic cancer signature (aerobic glycolysis) is reversible, rather than a consequence of permanent mitochondrial damage. Szent-Gyorgyi concluded this but this was also the conclusion of Koch (1958, see below) whose work strongly suggested that the metabolic/mitochondrial abnormality in cancers could be reversed. DCA was shown to significantly decrease tumour growth in rats without toxic effects. At this time, though approved as a drug treatment for mitochondrial diseases in humans, and apart from anecdotal reports, there are no formal clinical trials in patients with cancer.

Dr. William Koch’s research (1958) focused on the means to restore the body’s oxidation mechanism back to its original vitality, thereby re-equipping the body with its innate ability to restore and maintain health, not only in cancers but also in a host of other diseases.

Organized Medicine launched a fifty-year assault aimed at discrediting Dr. Koch’s reputation; medical practice and research, along with those of any physician who dared to validate his Theories or use his Reagents. Dr Koch’s theories emphasized the relationship between environmental toxins, dietary deficiencies and a depleted oxidation mechanism, as primary initiators of the disease process.

In his work he discovered that removal of the parathyroid gland of animals led to accumulation of toxic substances in the body. He also observed that the urine of the animals without parathyroid glands carried large amounts of lactic acid, which meant that the oxidation process was badly handicapped by the substances that were produced in the parathyroidectomized animals. These substances had blocked the normal tissue oxidation process. This turned out to be a momentous discovery, which paved the way for his original cancer research. By studying the tissues that survived the longest, he found out that the common feature was the presence of the di-carbonyl groups. He postulated that the toxic amines of various metabolic, bacterial, viral or of fungal agents (present day antibiotics included) are able to cripple these important carbonyls by condensing with them. These functional carbonyls were crucial to the preservation of electron transport and metabolic function of the cell but when they were complexed by toxins this could lead to an irreversible compromise of metabolic function. Unfortunately Dr. Koch was never given the research facilities and cooperation by the medical profession he had asked for and wanted.

Despite several cases of advanced cancers being treated successfully by Koch (by the injection of carbonyl compounds) in 1919 under the auspices of the Wayne County Medical Society branch of the American Medical Association (AMA), the Journal of the A.M.A. published over 20 negative editorials and articles about Dr. Koch and his treatment dating back to February 12, 1921.

In 1968, Dr. Szent-Gyorgyi also wrote about the cancerostatic action of carbonyl compounds (Szent-Gyorgyi et al, 1967) and how they are able to arrest cell division. He described these substances in urine and also in tissue extracts from several body organs. His research suggested that these substances when present are not only able to inhibit cell proliferation but also to maintain cells in a normal oxidative metabolism. The suggestion is that the body can lose its ability or become compromised in its ability to produce these substances thereby encouraging the development of cancer.

Further evidence that compromised mitochondrial function is a fundamental cause of the development of cancer is also suggested by the reported efficacy of the Kucera cancer support regime. Dr Michael Kucera, a Czech physician, has spent 20 years or more researching mitochondrial medicine and has developed nutritional combinations for mitochondrial support (Personal communication, 2009). A combination of these nutrients with specific immune support nutrients has led to remarkable success in cancer remissions. Over 700 cancer patients have been treated with this regime during the last 10 years. These have been patients with variable cancers, most of them non-localised i.e. they have already spread (including breast, prostate, colon and gastric cancers). Overall a 70% remission at 5 years is reported and an 80-90% remission when the formulas are combined with chemotherapy. No side effects were observed. Compare this to the efficacy of chemotherapy of 2-3% and with significant side effects. To my knowledge this may be the most effective treatment regime available and is the regime of choice used in my own clinic. It is even more remarkable that the regime is a purely oral-based regime. The fundamental basis for this high level of efficacy must be due to the core benefit to the mitochondria.

Coenzyme Q10 will be more familiar to many of you. This fat-soluble substance is present in most eukaryotic cells, primarily in the mitochondria. It is a component of the electron transport chain and participates in aerobic cellular respiration, generating energy in the form of ATP. Ninety-five percent of the human body’s energy is generated this way (Ernster & Dallner, 1995; Dutton et al, 2000) Therefore; those organs with the highest energy requirements—such as the heart and the liver—have the highest CoQ10 concentrations (Okamato et al, 1989; Aberg et al, 1992; Shindo et al, 1994).

Interest in coenzyme Q10 as a potential therapeutic agent in cancer was stimulated by an observational study that found that individuals with lung, pancreas, and especially breast cancer were more likely to have low plasma coenzyme Q10 levels than healthy controls (Folkers et al, 1997). There are a few case reports and an uncontrolled trial (see below) suggesting that coenzyme Q10 supplementation may be beneficial as an adjunct to conventional therapy for breast cancer (Hodges et al, 1999).

Although CoQ10 is best documented in the treatment of heart failure, two medical journal articles suggest tremendous promise in the treatment of cancer. Folkers (1997) described 10 cancer patients given CoQ10 for heart failure. One of the patients, a 48-year-old man diagnosed with inoperable lung cancer, had no signs of either cancer or heart failure symptoms while taking CoQ10 for 17 years.

Knud Lockwood, M.D (1994), a cancer specialist in Copenhagen, Denmark, described his treatment of 32 “high-risk” breast cancer patients with antioxidant vitamins, essential fatty acids, and CoQ10. “No patient died and all expressed a feeling of well-being,” he wrote “These clinical results are remarkable …..After 24 months, all still survived; about 6 deaths would have been expected.” Six of the 32 patients showed partial tumour remission, and two benefited from very high doses of CoQ10. One, a 59-year-old woman with a family history of breast cancer, had a tumour tumour recurrence 1.5-2 centimetres in diameter but one month after increasing the CoQ10 intake to 390 mg. daily, the tumour had disappeared. Mammography confirmed its absence. Another patient, age 74, had a small tumour removed from her right breast. She refused a second operation to remove additional growths and began taking 300 mg of CoQ10 daily. Three months later, an examination and mammography revealed no evidence of the tumour or metastases. Lockwood, who has apparently treated some 7,000 cases of breast cancer over 35 years, wrote that until using CoQ10, he had “never seen a spontaneous complete regression of a 1.5-2.0 centimetre breast tumour, and has never seen a comparable regression on any conventional anti-tumour therapy.”

Although none of the above are controlled studies they provide circumstantial evidence for my hypothesis that mitochondrial metabolic malfunction are critical to cancer development and should be the primary target in the war against cancer. Indeed, I have presented evidence from several pioneering doctors/researchers to show that when the mitochondria are supported and/or their metabolic defect is corrected that this is associated with cancer remissions. I am not the first to suggest this but I cannot ignore the evidence before me. I am convinced that this is the key to unravelling the cancer mystery. History has given us the clues…..it is time to stop ignoring them!

It was not the purpose of this article to focus on anything but the physical side of treatment but it would be an omission in the context of the title of this article “Winning the war on cancer” not to at least comment on the role of belief and positive thought to influence positive outcome in the war. This important component has been discussed elsewhere (Byrne, 2006; Chopra, 1989).

~ References ~

1. Aberg,F.et al. Archives of Biochemistry and Biophysics.1992, 295, 230-234

2. Bonnet,S; Archer, SL; Allalunis-Turner,J Haromy, A; Beaulieu,C; Thompson,R; Lee,CT;. Lopaschuk, GD; Puttagunta,; Bonnet, S; Harry, G; Hashimoto, K; Porter, CJ; Andrade, MA; Thebaud, B and Michelakis, ED. A Mitochondria-K+ Channel Axis Is Suppressed in Cancer and Its Normalization Promotes Apoptosis and Inhibits Cancer Growth. Cancer Cell, 2007, 11, 37–51.

3. Byrne, R. The Secret. 2006. Simon & Schuster Ltd

4. Chopra, D. Quantum Healing: Exploring the Frontiers of Mind/Body medicine. Bantam books, New York, 1989

5. Dutton PL, Ohnishi T, Darrouzet E, Leonard, MA, Sharp RE, Cibney BR, Daldal F and Moser CC. 4 Coenzyme Q oxidation reduction reactions in mitochondrial electron transport (pp 65-82) in Coenzyme Q: Molecular mechanisms in health and disease edited by Kagan VE and Quinn PJ, CRC Press (2000), Boca Raton

6. Ernster L, Dallner G: Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995,1271: 195-204,

7. Folkers K, Osterborg A, Nylander M, Morita M, Mellstedt H. Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun. 1997;234(2):296-299.

8. Goldblatt, H; and Cameron, G. Induced Malignancy In Cells From Rat Myocardium Subjected To Intermittent Anaerobiosis During Long Propagation In Vitro. The Journal of Experimental Medicine, 1953, 97, 525-552.

9. Hegyeli, A; McLaughlin, JA; Szent-Gyorgi, A. Preparation of Retine from Human Urine. Science: 1963, 142, 1571-1572

10. Hodges S, Hertz N, Lockwood K, Lister R. CoQ10: could it have a role in cancer management? Biofactors.1999;9(2-4):365-370.

11. Kim, JW and Dang, CV. Multifaceted roles of glycolytic enzymes. Trends Biochem. Sci. 2005, 30, 142–150.

12. Koch, WF. 1958. The Survival Factor in Neoplastic and Viral Disease.

13. Lockwood, K. Biochemical and Biophysical Research Communications.1994,199, 1504-8

14. Modica-Napolitano, JS & Aprille, JR. Basis for the selective cytotoxicity of rhodamine 123. Cancer Res, 1987, 47, 4361-4365

15. Modica-Napolitano, JS & Singh, KK. Mitochondria as Targets for Detection and Treatment of Cancer. Expert Reviews in Molecular Medicine. http://www-ermm.cbcu.cam.ac.uk. 2002, pp1-19

16. Okamoto, T.et al. Interna.J.Vit.Nutr.Res.1989,59,288-292

17. Petit, PX & Kroemer, G. Mitochondrial regulation of apoptosis. In Mitochondrial DNA Mutations in Aging, Disease and Cancer (Singh KK ed), pp147-165, Springer-Veerlag, Berlin

18. Plas, DR., and Thompson, CB. Cell metabolism in the regulation of programmed cell death. Trends Endocrinol. Metab, 2002, 13, 75–78.

19. Shindo, Y., Witt, E., Han, D., Epstein, W., and Packer, L., Enzymic and non-enzymic antioxidants in epidermis and dermis of human skin, Invest. Dermatol. 1994,102, 122-124.

20. Szent-Gyorgi, A. Bioelectronics and Cancer. Bioenergetics, 1973, 4, 533-562

21. Szent-Gyorgi, A; Egyud LG; McLaughlin, JA. Keto- Aldehydes and Cell Division. Science: 1967, 155, 539-541

22. Szent-Gyorgi, A; Hegyeli, A; McLaughlin, JA. Cancer Therapy: A Possible New Approach. Science: 1963, 140, 1391-1392

23. Warburg, O. 1930. Metabolism of Tumours. (London: Constable).

24. Woods, MW & DuBuy, HG. Cytoplasmic diseases and cancer. Science: 1945,102, 591-593

25. Zamzami, N et al. Mitochondrial control of nuclear apoptosis. J Exp Med, 1996, 183, 1533-1544

Researched and written by Dr. Nyjon Eccles, BSc, MBBS, MRCP, Ph.D. and published by International Aging Systems (IAS) in 2009.

Nearly 10 years later – little has changed! ~ Ed.

Part I: Losing the War on Cancer

Part II: Winning the War on Cancer

FAIR USE NOTICE: This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U. S. C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml